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ABSTRACT
Background: Group face-to-face and individual internet-based mindfulness-based cognitive therapy
(MBCT and eMBCT) have been demonstrated to reduce psychological distress for distressed cancer
patients in a randomized controlled trial (RCT). This study focused on the long-term effects of this RCT
during the nine-month follow-up period, and on possible predictors, moderators and work-
ing mechanisms.
Methods: Distressed cancer patients (n¼ 245) were randomized to MBCT or eMBCT. Data were col-
lected at baseline, post-treatment, three- and nine-month follow-up. Data were analyzed with linear
mixed effect models and (hierarchical) linear regressions.
Results: Analyses revealed long-term reductions in psychological distress and rumination, and
long-term increases in positive mental health and mental health-related quality of life (QoL) in both
interventions over the course of the nine-month follow-up. Interestingly, patients reported less psycho-
logical distress in the follow-up period after eMBCT in comparison to MBCT. Less psychological distress,
rumination and neuroticism, and more extraversion and agreeableness at baseline predicted less psy-
chological distress at the nine-month follow-up after both interventions. Less mindful and conscien-
tious patients at baseline benefited more from eMBCT than from MBCT. Regarding working
mechanisms, changes in mindfulness skills, fear of cancer recurrence and rumination during both inter-
ventions predicted less psychological distress at follow-up.
Conclusions: Our findings suggest most improvements in cancer patients’ increase over time after
both interventions. Furthermore, patients seemed to benefit more from eMBCT than MBCT based on
psychological distress levels, especially those patients with low levels of mindfulness skills and
conscientiousness.
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Introduction
Cancer is one of the leading causes of morbidity and mortal-
ity worldwide, and the number of cases is expected to
increase by 70% in the upcoming two decades [1]. Receiving
a cancer diagnosis and undergoing cancer treatment have a
major impact on patients. Not surprisingly, one in three
patients experiences significant psychological distress [2,3].
Especially anxiety disorders are common in cancer survivors,
with prevalence rates of almost one in five [4]. In turn, psy-
chological distress may result in worse outcomes. For
instance, anxiety and depression are related to lower quality
of life (QoL) in cancer patients [5], and depression might
even predict cancer progression and mortality [6].
In recent years, mindfulness-based cognitive therapy
[MBCT; 7] has proven to be an effective intervention to
reduce psychological distress in cancer patients [8–10].
Mindfulness is defined as ‘paying attention in a particular
way: on purpose, in the present moment, and non--
judgmentally’ [11, p. 4]. MBCT instructs patients in mindful-
ness skills and is usually delivered as eight-week group
training, including a so-called silent day.
The classical format of MBCT, with weekly group meetings,
poses a number of challenges for cancer patients. While
often suffering from fatigue [12], cancer patients have to
travel to the MBCT location on a fixed date and time, result-
ing in little flexibility and travel costs. Internet-based MBCT
(eMBCT), on the other hand, has a number of benefits, like
availability, but also flexibility in time and location [13].
A small waitlist randomized-controlled trial (RCT) about an
online group mindfulness-based intervention (MBI) for cancer
patients revealed positive effects on stress symptoms and
mood disturbances [14]. Moreover, an active-controlled study
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showed eMBCT could reduce cancer-related fatigue [15]. Our
research group conducted a large RCT (the BeMind project)
comparing group MBCT with individual eMBCT, showing that
both types of treatments are superior to usual care [16].
However, long-term effects, predictors/moderators and work-
ing mechanisms of both MBCT and eMBCT still need to be
addressed, which is the goal of this study.
Long-term effects
In a large meta-analysis, Piet et al. [8] found small to moder-
ate effects of MBIs for cancer patients in the long-term (on
average six months after the intervention), but concluded
this as preliminary evidence, due to the small amount of
studies that included long-term results. More recent random-
ized controlled trials for breast cancer patients showed that
intervention effects of MBIs persist, even up to one year after
the intervention [17,18].
Prediction/moderation
Although MBCT and eMBCT are beneficial for cancer patients
in general, not all patients respond to these interventions. In
order to guide clinical practice, research on predictors and
moderators is necessary to know what works for whom.
Predictors are variables that predict outcomes regardless of
treatment allocation, while moderators are variables that
influence the relationship between treatment and outcome,
answering the question which type of treatment works best
for whom [19]. In the field of MBIs for cancer, a small number
of studies focused on identifying predictors and moderators
of face-to-face MBIs. With regard to the demographic charac-
teristics, earlier research showed higher education predicted
stronger improvement from pre to post-treatment, while
gender and age did not predict outcomes in MBIs for cancer
patients [20]. Personality aspects (neuroticism, extraversion,
openness, agreeableness and conscientiousness) did not
moderate treatment outcome of a MBI for cancer patients
versus supportive-expressive therapy [21]. Presence of mood
or anxiety disorder(s) was associated with larger treatment
effects in face-to-face MBCT in patients with a range of med-
ical and psychiatric conditions [22]. Moreover, baseline psy-
chological distress and more generally, baseline complaints
moderated treatment outcome; patients with more severe
complaints benefited more from the intervention compared
to control [21,23–25].
Working mechanisms
Another way of advancing treatment research is by gaining a
deeper understanding of the working mechanism of an inter-
vention. This can help clinicians to identify the active compo-
nent of an intervention and tailor the program accordingly.
A small number of previous studies focused on this topic in
cancer patients. In breast cancer patients, fear of cancer
recurrence was a mediator for psychological and physical
outcomes [26]. Other studies found rumination and mindful-
ness skills as mediators of disturbed mood in cancer patients
[27,28], although findings seemed mixed [29]. A large meta-
analysis combining psychiatric and medical conditions also
found rumination and mindfulness skills as mediators of
MBIs [30].
Research questions
This study reports on the long-term effects of MBCT and
eMBCT in cancer patients who experience at least mild psy-
chological distress [31]. We expected our primary outcome
(psychological distress) and secondary outcomes (fear of
cancer recurrence, rumination, positive mental health,
health-related QoL) to remain stable over the course of the
follow-up, without a difference between MBCT and eMBCT,
as they are similar in content. In addition, we studied predic-
tion and moderation of treatment outcome in MBCT versus
eMBCT. Potential predictors and moderators were gender,
age, level of education, work, anticancer treatment intent,
presence of depressive and/or anxiety disorder, personality
traits, baseline psychological distress, fear of cancer recur-
rence, rumination and mindfulness skills. These predictors
and moderators were studied exploratory. Finally, this study
investigated whether change in fear of cancer recurrence,
rumination and mindfulness skills over (e)MBCT, could predict
psychological distress at the last follow-up. We expected that
decreases in fear of cancer recurrence and rumination, and
increases in mindfulness skills during (e)MBCT predict psy-
chological distress at the nine-month follow-up.
Material and methods
This study involved the follow-up data from a three-armed,
multicenter and randomized controlled trial. Participants
were randomized into one of three conditions; face-to-face
group MBCT, individual eMBCT or treatment as usual (TAU).
Patients in the TAU condition were randomized to MBCT or
eMBCT after they had completed the three-month TAU
period, thus, follow-up data is only available for MBCT and
eMBCT. Information regarding inclusion of participants and
content of the intervention is described in the study protocol
[31]. The study was approved by an ethical review board
(CMO Arnhem-Nijmegen, registered under number 2013/542).
Participants
Participants were recruited through various online (e.g.,
Facebook) and offline (e.g., newspapers) media. Interested
patients were directed to a study website, containing further
information. Inclusion criteria were having any cancer diagno-
sis; experiencing at least mild psychological distress [a score
of 11 on the Hospital Anxiety and Depression Scale (HADS)
that patients could fill out on the study website; 32,33]; com-
puter literacy and internet access; good command of the
Dutch language; and willingness to participate in either
mindfulness intervention. Potential participants could self-
enroll for the study if they fulfilled the inclusion criteria,
which were verified in a face-to-face or telephone interview.
Exclusion criteria were severe psychiatric morbidity, change
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in psychotropic medication within three months of baseline,
and current or previous participation in MBCT or MBSR. More
details about the recruitment procedure can be found else-
where [31].
Procedure
Patients eligible for the study were randomized to one of the
three arms: MBCT, eMBCT or TAU. Patients in the TAU condi-
tion were randomized to the MBCT or eMBCT after a three-
month period. Participants filled out questionnaires after ran-
domization (baseline, T0), directly after the intervention (T1),
and at three-month (T2) and nine-month (T3) follow-up.
Participants in TAU completed an additional assessment
(T0b) at the end of the three-month TAU period.
Interventions
The content of the MBCT and eMBCT was similar, and based
on the MBCT program of Segal et al. [34]. Minor adaptations
were made to the program to suit the needs of cancer
patients, in terms of psycho-education (e.g., about cancer-
related fatigue) and movement exercises (e.g., suitable for
patients with edema). In each MBCT group, a maximum of 12
patients participated. For eight weeks, patients had weekly
2.5 h sessions, and they were requested to practice at home
on a daily basis (45min a day and six days a week). Between
session six and seven, there was a silent day. For eMBCT, each
participant was provided with information and exercises
through a personal, secure webpage containing material for
the eight sessions and the silent day. Participants were encour-
aged to read the information and do the exercises of a session
within one week. Participants reflected on their experiences by
keeping a personal log. The therapist assigned to the partici-
pant gave weekly written feedback based on this log on a set
day of the week through a secured, integrated e-mail system,
guiding the patient through the program. Therapists could
encourage patients and answer their questions, they could ask
questions to deepen understanding of patients, and help
patients to overcome the obstacles they encountered through
the e-mails. Different themes could be discussed, for example,
growing awareness about automatic tendencies like perfec-
tionism, or resistance to feel an unpleasant sensation like a
headache. Therapists could spend 30min per patient per week
on feedback in eMBCT.
Both MBCT and eMBCT were taught by qualified mindfulness
therapists, according to the criteria of the UK Mindfulness-Based
Teacher Network [35]. Seven therapists provided both interven-
tions, two provided only MBCT and five provided only eMBCT.
All therapists attended three full-day supervision meetings.
MBCT sessions were videotaped to rate therapist competency
with the Mindfulness-Based Interventions – Teachers
Assessment Criteria [MBI-TAC; 36] by two independent thera-
pists (inter-rater reliability was 0.72). Randomly, two sessions of
each of the nine MBCT therapists were rated; four were consid-
ered 'proficient' (n¼ 64 patients), three 'competent' (n¼ 64
patients) and two 'beginner' (n¼ 7 patients).
Material
Outcome measures
The primary outcome measure was psychological distress,
measured with the 14-item Hospital Anxiety and Depression
Scale (HADS), developed to measure depression and anxiety
[32,33]. The HADS has adequate psychometric properties to
detect distress in cancer patients and is a suitable screening
instrument for psychiatric disorders in this group [37,38].
Internal consistency in this study was good (Cronbach’s a
at T0¼ 0.87).
The secondary outcome measures were fear of cancer
recurrence, rumination, positive mental health and health-
related quality of life. Fear of cancer recurrence was meas-
ured with the 9-item Severity subscale of the Fear of Cancer
Recurrence Inventory [FCRI; 39,40]. Internal consistency was
good (a¼ 0.85). Rumination was measured with the 12-item
rumination subscale of the Rumination and Reflection
Questionnaire [RRQ; 41]. Internal consistency was excellent
(a¼ 0.91). Positive mental health was measured with the 14-
item Mental Health Continuum-Short Form [MHC-SF; 42,43].
Internal consistency was excellent (a¼ 0.92). Health-related
QoL was measured with the 12-item Short Form-12 [SF-12;
44]. Clinical Dutch norms were used to calculate two sub-
scales, physical and mental health-related QoL [45].
Predictors/moderators
Tested predictors/moderators were gender, age, education
level, work, anticancer treatment intent, presence of depres-
sive and/or anxiety disorder, personality, baseline psycho-
logical distress, fear of cancer recurrence, rumination and
mindfulness skills. Sociodemographic and clinical characteris-
tics were assessed via a self-report questionnaire.
Presence of a depressive or anxiety disorder (according to
DSM-IV) was assessed with the relevant sections of the
Structural Clinical Interview for DSM-IV disorders [SCID-I; 46].
The SCID-I was administered by trained interviewers.
Personality was assessed with the NEO Five Factor Inventory
[NEO-FFI; 47]. This 60-item self-report questionnaire measures
five personality characteristics; openness to experiences, con-
scientiousness, extraversion, agreeableness and neuroticism.
Mindfulness skills were measured with the Five Facet
Mindfulness Questionnaire Short Form (FFMQ-SF), a 24-item
self-report questionnaire [48]. Internal consistency was
good (a¼ 0.85).
Working mechanisms
Tested working mechanisms were fear of cancer recurrence
(FCRI), rumination (RRQ) and mindfulness skills (FFMQ) (meas-
ures described above).
Statistical analyses
To facilitate transparency, the data-analysis plan was pre-reg-
istered online at Open Science Framework (https://osf.io/
v9ud8/). Adaptations to the analysis plan were tracked. All
analyses were conducted in SPSS version 22 (IBM SPSS
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Statistics, Armonk, NY, USA) [49]. The mean percentage of
missing data for the follow-up assessments of our primary
outcome, combining both interventions and TAU, varied
between 25 and 30% (see Figure 1 for a flowchart).
Participants that missed T3 (primary outcome) had less posi-
tive mental health and more fear of cancer recurrence,
rumination and neuroticism at T0 and they were more likely
to be females. Therefore, we assumed data were not missing
completely at random, but missing at random (MAR), allow-
ing procedures to handle missing data, described below. For
the TAU group, T0 scores on the primary and secondary out-
come measures were replaced with T0b (post-TAU) scores, as
those were closer in time to the start of the intervention.
These scores did not differ from T0 of the original MBCT and
eMBCT group. In all analyses, data of patients that followed
(e)MBCT after TAU were combined with data of patients that
were initially randomized to (e)MBCT.
Long-term effects
To examine long-term effects, we used linear mixed effect
models with the primary outcome or secondary outcomes at
T1, T2 and T3 as dependent variable. Independent variables
were time (nested in individuals), intervention (MBCT/
Randomized
n = 245
MBCT
n = 77, 31.4%
eMBCT
n = 90, 36.7%
TAU
n = 78, 31.8%
Completed T0
n = 77, 100%
Completed T0
n = 90, 100%
Completed 
TAU
n = 77, 98.7%
Completed 
MBCTa
n = 64, 83.1%
Completed 
eMBCTa
n = 63, 70.0%
Completed T1
n = 64, 81.3%
Completed T0b 
n = 70, 89.7%
Completed T1
n = 75, 83.3%
MBCT
n = 43, 55.1%
eMBCT
(n=77, 31.4%)
Completed T2 
n = 66, 85.7%)
Completed T2 
n = 74, 82.2% eMBCT
n = 35, 44.9%
Completed 
MBCTa
n = 20, 46.5%
Completed 
eMBCTa
n = 16, 45.7%
Completed T1
n = 26, 60.5%
Completed T1
n = 18, 51.4%
Completed T2 
n = 23, 53.5%
Completed T2 
n = 21, 60.0%
Completed T3
n = 58, 75.3%
Completed T3
n = 68, 75.5%
Completed T3
n = 26, 60.5%
Completed T3
n = 19, 54.3%
Completed T0
n = 78, 100%
Figure 1. Flowchart indicating randomization, completion of interventions and assessments (based on the primary outcome). aCompleted at least four sessions.
T0¼ pre-measure, T0b¼ post-TAU measure, T1¼ post-intervention; T2¼ three-month follow-up; T3¼ nine-month follow-up.
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eMBCT), their interaction and the baseline measure (T0) of
the outcome. Visual inspection of residual plots revealed lin-
ear relationships between time and outcomes, allowing us to
treat time as covariate, to draw conclusions regarding gen-
eral increases and decreases of outcomes over time. In case
of a non-significant interaction, the model was rerun without
the interaction. Random intercepts for participants were
added. A heterogeneous first-order autoregressive (ARH(1))
covariance structure was used, which assumes measurements
closer in time are more strongly related. Restricted maximum
likelihood was used as estimation method, to handle missing
data [50]. In case of a significant difference between inter-
ventions, effect sizes (Cohen’s d) were calculated with the dif-
ference between the estimated marginal means of the
interventions, corrected for T0, divided by the pooled
baseline standard deviation, following the guidelines of
Cohen [51].
Prediction/moderation
To examine prediction, we conducted separate linear regres-
sion models. Psychological distress at T3 acted as dependent
variable. Independent variables were the baseline level of
psychological distress, intervention (MBCT/eMBCT) and the
baseline characteristic (testing prediction). To test moder-
ation, we used the same model, but added the interaction
between the baseline characteristic and the intervention. As
these analyses were exploratory, an alpha level of 0.05 was
used. Analyses were run on the completer data, and on
imputed data, as sensitivity analysis. Missing data were
imputed with the Fully Conditional Specification method,
based on all variables included in the models, and the strati-
fication variables (gender, location, treatment intention and
breast cancer yes/no). Following guidelines of White et al.
[52], 30 imputed datasets were created, representing the
maximum % of missing data.
Working mechanisms
To examine working mechanisms, data from participants that
completed four or more sessions were included. Residual
change scores of fear of cancer recurrence, rumination and
mindfulness skills from T0 to T1 were calculated. Next,
separate hierarchical linear regression models were run. Step
1 was identical for the three regressions, and included base-
line psychological distress and intervention (MBCT/eMBCT). In
step 2, the residual change score was added, to test the
added contribution in the model. Psychological distress at T3
acted as dependent variable. Analyses were run on the com-
pleter data, and on imputed data, as sensitivity analysis.
Missing data were imputed following the same procedure as
described above.
Results
The final sample consisted of 245 cancer patients with at
least mild psychological distress (HADS 11). Baseline charac-
teristics can be found in Table 1. No baseline differences
were found between participants in eMBCT and MBCT,
except for mindfulness skills, with significantly higher levels
of mindfulness skills in eMBCT.
Long-term effects
The results of the linear mixed effect models regarding the
long-term effects of MBCT and eMBCT on the primary and
secondary outcomes can be found in Table 2. None of the
time  intervention interactions were significant; therefore,
these were excluded from the models. In contrast to our
expectations, rather than remaining stable, the level of psy-
chological distress further decreased over the course of the
follow-up in both interventions. Furthermore, participants in
eMBCT reported less psychological distress during the follow-
up period compared to participants in MBCT. The effect size
for the difference between groups at T3, corrected for T0,
was small (Cohen’s d¼ 0.22).
With regard to the secondary outcome measures, rumin-
ation significantly decreased over the nine-month follow-up
in both MBCT and eMBCT. Furthermore, positive mental
health and mental health-related QoL significantly increased
over the course of the nine-month follow-up. Fear of cancer
recurrence and physical health-related QoL did not signifi-
cantly change over time. There were no differences between
MBCT and eMBCT on the secondary outcomes.
Table 1. Sample characteristics per intervention (MBCT/eMBCT) at T0.
MBCT (n¼ 120) eMBCT (n¼ 125) Test-statistic (t or v2) p
Gender (n, %) Male 19 (15.8%) 16 (12.8%) 0.46 .498
Female 101 (84.2%) 109 (87.2%)
Age in years (M; SD) 51.5 (11.1) 51.8 (10.2) 0.18 .857
Education level (n, %) Low/middle 35 (29.2%) 44 (35.2%) 1.02 .312
High 85 (70.8%) 81 (64.8%)
Type of cancer (n, %) Breast 75 (62.5%) 76 (60.8%) 0.08 .784
Other 45 (37.5%) 49 (39.2%)
Type of treatment (n, %) Curative 104 (86.7%) 102 (81.6%) 1.17 .279
Palliative 16 (13.3%) 23 (18.4%)
Depressive and/or anxiety disorder (n, %) 35 (29.2%) 34 (27.2%) 0.12 .732
Psychological distress HADS (M; SD) 18.2 (6.7) 16.8 (6.9) 1.64 .103
Fear of cancer recurrence severity FRCI (M; SD) 21.2 (6.6) 21.1 (6.3) 0.04 .970
Rumination RRQ (M; SD) 43.6 (8.2) 42.4 (8.4) 1.16 .247
Mindfulness FFMQ-SF (M; SD) 73.5 (10.4) 77.1 (11.2) 22.55 .011
Both categories include the patients that were initially randomized to the TAU group.
Bold values represent statistically significant differences.
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Prediction/moderation
Table 3 shows the results of the linear regression models to
determine prediction of treatment effect. In all analyses,
more baseline psychological distress predicted more psycho-
logical distress at the nine-month follow-up. With regard to
predictors, baseline rumination, extraversion, agreeableness
and neuroticism predicted psychological distress at the nine-
month follow-up. More rumination and neuroticism were
related to more psychological distress at nine-month follow-
up. More extraversion and agreeableness were related to less
psychological distress at nine-month follow-up. These results
were confirmed with sensitivity analyses on the imputed
data. No other significant predictors were found. Regarding
moderation (Table 4), we found that mindfulness skills and
conscientiousness moderated the relationship between the
intervention and psychological distress at nine-month follow-
up (controlling for baseline psychological distress). Patients
who were less mindful and conscientious at baseline had
lower psychological distress at the nine-month follow-up in
the eMBCT intervention than in the MBCT intervention. This
was confirmed in sensitivity analyses on the imputed data.
No other moderators were found.
Working mechanisms
Results of the three hierarchical regressions analyses testing
working mechanisms can be found in Table 5. The residual
change scores of fear of cancer recurrence, rumination and
mindfulness skills all added a significant contribution in step
2. A decrease in rumination and fear of cancer recurrence,
and an increase in mindfulness skills over the course of
(e)MBCT predicted lower levels of psychological distress at
Table 2. Descriptive statistics and effects of time, intervention and baseline on primary and secondary outcomes in separate linear mixed effect
models.
Descriptive statistics
Results linear mixed modelsM (SD)
MBCT eMBCT F df p
Primary outcome:
Psychological distress (HADS) T1 13.5 (6.5) 11.6 (6.2) T0 HADS 130.2 1, 199 <.001
T2 12.9 (7.2) 11.1 (7.0) Time 14.3 1, 178 <.001
T3 12.6 (6.7) 9.6 (6.4) Intervention 3.9 1, 201 .049
Secondary outcomes:
Fear of cancer recurrence severity (FCRI- severity) T1 17.9 (6.7) 17.0 (7.5) T0 FCRI 272.0 1, 196 <.001
T2 16.7 (5.4) 16.3 (5.5) Time 1.2 1, 157 .282
T3 17.3 (6.4) 16.3 (6.7) Intervention 1.6 1, 191 .201
Rumination (RRQ – rumination) T1 37.9 (8.6) 36.0 (8.9) T0 RRQ – rum 146.4 1, 190 <.001
T2 37.3 (7.6) 35.4 (8.3) Time 38.4 1,185 <.001
T3 34.6 (5.8) 33.9 (6.1) Intervention 0.5 1, 194 .489
Positive mental health (MHC-SF) T1 40.1 (12.9) 43.4 (13.2) T0 MHC-SF 191.9 1, 195 <.001
T2 39.7 (13.7) 46.2 (11.8) Time 21.7 1, 169 <.001
T3 43.6 (13.7) 48.3 (12.2) Intervention 2.7 1, 190 .101
Physical health-related QoL (SF-12 PCS) T1 48.5 (8.2) 47.8 (10.1) T0 SF-12 PCS 76.7 1, 198 <.001
T2 47.2 (9.2) 47.5 (9.3) Time 0 1, 177 .995
T3 48.3 (9.4) 47.8 (10.5) Intervention 0.3 1, 192 .610
Mental health-related QoL (SF-12 MCS) T1 42.6 (10.2) 43.8 (10.6) T0 SF-12 MCS 52.9 1, 191 <.001
T2 45.4 (11.0) 47.0 (11.8) Time 25.5 1, 172 <.001
T3 46.5 (11.5) 48.9 (10.6) Intervention 1.8 1, 197 .182
All time  intervention interactions were non-significant, and, therefore, excluded from the models. T1¼ post-treatment; T2¼ three-month
follow-up; T3¼ nine-month follow-up.
Table 3. Relationship between predictor (corrected for baseline psychological distress and the main effect of intervention) and psychological
distress at the nine-month follow-up with separate linear regressions (completer data).
Variable
Full model Predictor
F-value (df) p Adjusted R2 B t p
Psychological distress (T0) 39.11 (2, 167) <.001 0.311 0.51 8.16 <.001
Gender 26.59 (3, 166) <.001 0.312 1.32 1.18 .242
Age: younger than 40 yearsa 21.12 (4, 165) <.001 0.323 0.68 0.50 .616
Age: older than 55 yearsa 1.74 1.89 .060
Education level (high/low) 26.02 (3, 166) <.001 0.308 0.43 0.45 .653
Work (3 d or more, less than 3 d) 13.03 (3, 103) <.001 0.254 0.19 0.16 .870
Anticancer treatment intent 25.93 (3, 166) <.001 0.307 0.18 0.15 .882
DSM depressive/anxiety disorder 26.10 (3, 166) <.001 0.308 0.64 0.60 .550
Personality – openness 25.95 (3, 166) <.001 0.307 0.02 0.25 .800
Personality – conscientiousness 27.57 (3, 166) <.001 0.320 0.13 1.84 .068
Personality – extraversion 30.35 (3, 166) <.001 0.343 0.22 3.01 .003
Personality – agreeableness 31.06 (3, 166) <.001 0.348 0.32 3.24 .001
Personality – neuroticism 30.30 (3, 166) <.001 0.342 0.22 2.99 .003
Fear of cancer recurrence – severity 25.81 (3, 165) <.001 0.307 0.02 0.29 .773
Rumination 28.39 (3, 165) <.001 0.328 0.13 2.32 .022
Mindfulness 26.37 (3, 166) <.001 0.311 0.04 0.96 .338
aReference category was age 40–55 years.
Bold values represent statistically significant effects.
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the nine-month follow-up. These results were confirmed with
sensitivity analyses on the imputed data.
Discussion
This study focused on long-term outcome, prediction, moder-
ation and working mechanisms of MBCT and eMBCT for dis-
tressed cancer patients.
Long-term effects
In contrast to our expectations, psychological distress and
rumination further decreased and positive mental health and
mental health-related QoL further increased over the dur-
ation of the follow-up period in both interventions. A few
other studies on MBIs for cancer patients also reported fur-
ther improvements over the course of follow-up [e.g., 53]. It
is possible that the cumulative practice of mindfulness
resulted in increased gains over time. This observation fits
with the idea of mindfulness as a mental training [54], that
keeps improving with practice like a muscle, as suggested by
Parsons et al. [55]. Fear of cancer recurrence and physical
health-related QoL did not change over time, suggesting
improvements gained during the training remain stable over
the course of the follow-up, as expected.
Furthermore, eMBCT appeared to be superior to MBCT in
the reduction of psychological distress during the follow-up
period. So far, research has shown online and face-to-face
interventions to produce similar effects, as is reported in a
large meta-analysis about the comparison of online and face-
to-face cognitive behavioral therapy for patients with somatic
and psychiatric disorders [56]. As MBCT and eMBCT were
similar in content, the delivery method might explain why
eMBCT resulted in a greater reduction of psychological dis-
tress during the follow-up. From the start of the training, par-
ticipants in eMBCT had to be more autonomous. This
autonomy might help to form the habit of more actual mind-
fulness practice [57], which we know is related to better
treatment outcomes [55]. Furthermore, the flexibility allowed
by eMBCT could result in practice at a time the participant
was ready to absorb information, which might also support
the efficacy of eMBCT. Finally, it is also possible that the indi-
vidual nature of eMBCT, compared to group MBCT, contrib-
uted to the greater efficacy. The individual attention of a
therapist in eMBCT might serve as a catalyst for mindfulness
practice or might be more compatible with the individual
needs of the cancer patients.
Prediction/moderation
Baseline psychological distress, rumination, neuroticism,
extraversion and agreeableness predicted treatment outcome
Table 4. Relationship between moderator (i.e., predictor x intervention interaction; corrected for baseline psychological distress and
the main effect of intervention) and psychological distress at the nine-month follow-up with separate linear regressions (com-
pleter data).
Variable (x intervention)
Full model Moderator
F-value (df) p Adjusted R2 B t p
Psychological distress (T0) 26.36 (3, 166) <.001 0.310 0.12 0.95 .342
Gender 20.61 (4, 165) <.001 0.317 3.29 1.46 .148
Age: younger than 40 yearsa 14.13 (6, 163) <.001 0.318 2.53 0.93 .357
Age: older than 55 yearsa 0.82 0.45 .655
Education level (high/low) 19.6 (4, 165) <.001 0.306 1.40 0.73 .467
Work (3 d or more, less than 3 d) 10.01 (4, 102) <.001 0.254 2.36 0.98 .328
Anticancer treatment intent 19.34 (4, 165) <.001 0.303 0.31 0.12 .902
DSM depressive/anxiety disorder 19.77 (4, 165) <.001 0.308 1.76 0.92 .357
Personality – openness 19.35 (4, 165) <.001 0.303 0.01 0.06 .953
Personality – conscientiousness 23.07 (4, 165) <.001 0.343 0.37 2.60 .010
Personality – extraversion 23.30 (4, 165) <.001 0.345 0.18 1.32 .189
Personality – agreeableness 23.15 (4, 165) <.001 0.344 0.01 0.03 .975
Personality – neuroticism 23.35 (4, 165) <.001 0.346 0.16 1.41 .161
Fear of cancer recurrence – severity 19.25 (4, 164) <.001 0.303 0.03 0.18 .858
Rumination 22.28 (4, 164) <.001 0.336 0.17 1.71 .088
Mindfulness 21.15 (4, 165) <.001 0.323 0.16 2.01 .046
aReference category was age 40–55 years.
Bold values represent statistically significant effects.
Table 5. Effects of change in fear of cancer recurrence/rumination/mindfulness (corrected for psychological distress at baseline and intervention) on psy-
chological distress at the three-month follow-up with hierarchical linear regressions (completer data).
Working mechanism Step-variable F df p DR2 B t p
Alla Step 1 29.63 2, 126 <.001 0.320
Psychological distress T0 0.49 6.77 <.001
Intervention (MBCT/eMBCT) 3.44 3.37 .001
Fear of cancer Step 2 6.42 1, 125 .013 0.033
Residual change score fear of cancer recurrence T0/T1 1.40 2.53 .013
Rumination Step 2 16.13 1, 125 <.001 0.078
Residual change score rumination T0/T1 1.99 4.02 <.001
Mindfulness Step 2 15.47 1, 125 <.001 0.075
Residual change score mindfulness T0/T1 2.01 3.93 <.001
Dependent variable: psychological distress at T3.
aFor all three working mechanisms, step 1 was identical.
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at nine-month follow-up in both eMBCT and MBCT, con-
trolled for baseline psychological distress. More baseline psy-
chological distress was related to more psychological distress
at the nine-month follow-up. More rumination and neuroti-
cism at baseline were related to more psychological distress
at the follow-up (even while controlling for baseline psycho-
logical distress). Thus, while patients improved after the inter-
ventions, it seems that patients with more severe complaints
at the start of the intervention had higher levels of distress
at the nine-month follow-up compared to their less dis-
tressed counterparts. Other studies [e.g., 25] also found that
patients with more baseline severity had more severe com-
plaints at the follow-up (even though more severe patients
benefit relatively more from MBIs compared to less severe
patients). Booster sessions might be indicated for this sub-
group of patients.
More extraversion and agreeableness predicted less psy-
chological distress at nine-month follow-up after both inter-
ventions. An earlier study found that when working in teams,
more extravert and agreeable people were more willing to
share what they think [58]. This willingness to share might
also occur in context of MBCT (with the therapist and other
patients) and eMBCT (with the therapist). By sharing more,
one is able to receive more input from others, which could
result in deepening of knowledge about mindfulness that
might enable more and faster learning. Furthermore, both
extraversion and agreeableness are related to more self-com-
passion [59]. As self-compassion forms a link between mind-
fulness and positive outcomes [60], more extraverted and
agreeable people could benefit more from MBCT and eMBCT,
resulting in less psychological distress.
With regard to moderation, patients with less mindfulness
skills and less conscientiousness benefited more from eMBCT
than MBCT on the long-term. It is possible that the individual
attention in eMBCT helped patients who are less mindful and
conscientious. Furthermore, while patients in MBCT can
refrain from discussing (the lack of) home practice by letting
others in the group share their experiences, patients in
eMBCT are more acknowledged for their home practice as
they receive weekly written feedback from their therapist on
it. Thus, eMBCT might encourage the less conscientious and
mindful patients to complete their homework. The absence
of other moderating variables implies that despite the com-
mon belief that older and less-educated patients might bene-
fit less from online interventions like eMBCT, they seemed to
do just as well as their younger and higher educated coun-
terparts, although the latter group was more represented in
our sample. Future studies are needed to replicate
these findings.
Working mechanisms
Finally, we found that a decrease in fear of cancer recurrence
and rumination, and an increase in mindfulness skills during
(e)MBCT were related to lower psychological distress nine
months after (e)MBCT, which confirmed our hypotheses.
These results are in accordance with previous research identi-
fying fear of cancer recurrence, rumination and mindfulness
skills as mediators [26,27,30]. Furthermore, these results are
in line with the mindfulness-to-meaning theory that explains
how mindfulness practice might decrease stress and rumin-
ation in adverse circumstances, through positive psycho-
logical processes [61], for which evidence was found in
cancer patients [62]. Future research on working mechanisms
is necessary and should include measuring positive psycho-
logical processes in addition to negative psycho-
logical processes.
Strengths and limitations
This study has a number of strengths. First of all, it is the first
in this field to directly compare MBCT and eMBCT which
were similar in content. Second, this study is one of the few
to focus on long-term effects of (e)MBCT for cancer patients
[8]. Third, due to promotion of the study website through
various online and offline media, cancer patients from out-
side the participating institutes could be reached. This inclu-
sion method might benefit the ecological validity of our
study. However, it could also have resulted in a self-selection
bias, as patients interested in mindfulness were probably
more likely to participate, which can be considered as a
drawback. Another limitation of this study is the absence of
data about the control condition at the follow-up. Due to
ethical constraints, we chose to offer patients randomized to
the TAU condition participation in one of the two interven-
tions after three months. This prevented us from testing
whether the improvement over time is due to the MBCT
interventions or whether this improvement is due to natural
recovery or regression to the mean, although we did not
observe this tendency in the TAU group during the three-
month waiting. Finally, patients that missed the nine-month
follow-up had worse complaints at baseline. As we miss the
results of this group in the analyses, an underestimation or
overestimation of effects is possible, although we used
restricted maximum likelihood estimation or imputation pro-
cedures to deal with missingness. Finally, as we had no con-
trol group, we were not able to do formal mediation
analyses, which limit our conclusions regarding work-
ing mechanisms.
Conclusions
To the authors’ knowledge, this study is the first to directly
compare an online and face-to-face version of MBCT for can-
cer patients. Results showed that patients kept improving
over time after both MBCT interventions over the nine-month
follow-up period, based on their level of psychological dis-
tress, rumination, positive mental health and mental health-
related QoL. Furthermore, we found eMBCT to be superior to
MBCT in terms of psychological distress reduction at nine-
month follow-up, especially for patients with less mindfulness
skills and conscientiousness, who seemed to benefit more
from eMBCT. No other baseline characteristics were differen-
tial moderators between the two conditions, so both MBCT
and eMBCT appeared to be suitable for a large range of can-
cer patients. Future research is necessary to confirm these
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claims and to include MBIs in the clinical guidelines for treat-
ment of distressed cancer patients.
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